Finepoint Capital LP Prothena Corp Public LTD CO Transaction History

Finepoint Capital LP

  • $963 Million
  • Q3 2024

A detailed history of Finepoint Capital LP transactions in Prothena Corp Public LTD CO stock. As of the latest transaction made, Finepoint Capital LP holds 433,471 shares of PRTA stock, worth $6.6 Million. This represents 0.75% of its overall portfolio holdings.

Number of Shares
433,471
Previous 433,471 -0.0%
Holding current value
$6.6 Million
Previous $8.95 Million 18.95%
% of portfolio
0.75%
Previous 2.58%

Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024
BUY
$19.54 - $26.15 $607,127 - $812,506
31,071 Added 7.72%
433,471 $8.95 Million
Q1 2024

May 14, 2024
BUY
$24.75 - $40.66 $1.31 Million - $2.16 Million
53,100 Added 15.2%
402,400 $9.97 Million
Q3 2023

Nov 13, 2023
BUY
$47.3 - $70.6 $1.51 Million - $2.26 Million
32,000 Added 10.09%
349,300 $16.9 Million
Q2 2023

Aug 11, 2023
SELL
$48.26 - $78.59 $690,118 - $1.12 Million
-14,300 Reduced 4.31%
317,300 $21.7 Million
Q1 2023

May 12, 2023
BUY
$46.97 - $58.27 $408,639 - $506,949
8,700 Added 2.69%
331,600 $16.1 Million
Q4 2022

Feb 13, 2023
BUY
$52.05 - $65.0 $910,875 - $1.14 Million
17,500 Added 5.73%
322,900 $19.5 Million
Q3 2022

Nov 10, 2022
SELL
$25.16 - $60.63 $3.83 Million - $9.22 Million
-152,100 Reduced 33.25%
305,400 $18.5 Million
Q2 2022

Aug 12, 2022
BUY
$22.73 - $39.98 $10.4 Million - $18.3 Million
457,500 New
457,500 $12.4 Million

Others Institutions Holding PRTA

# of Institutions
184
Shares Held
42.7M
Call Options Held
162K
Put Options Held
102K
View Full List

About PROTHENA CORP PUBLIC LTD CO

PRTA Quotes by TradingView
  • Ticker PRTA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,922,800
  • Market Cap $714M
  • Description
  • Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a human...
More about PRTA
Track This Portfolio

Track Finepoint Capital LP Portfolio

Follow Finepoint Capital LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Finepoint Capital LP, based on Form 13F filings with the SEC.

News

Stay updated on Finepoint Capital LP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email